Equity Research Report: Windlas Biotech Limited
Date: 07 February 2026
Current Market Price (CMP): ₹854 (approx)
Market Cap: ~₹1,800 Cr
Sector: Pharmaceuticals (CDMO)
1️⃣ Business Model & Work
Windlas Biotech India ki leading CDMO (Contract Development and Manufacturing Organization) companies me se ek hai. Ye khud ki dawaiyan (brands) kam bechte hain, balki dusri badi pharma companies ke liye dawaiyan banate hain.
- Core Business Verticals:
- CDMO Services (Main Revenue Source): Ye Pfizer, Sanofi, Zydus, Emcure jaisi badi companies ke liye contracts par medicines manufacture karte hain. (Focus: Chronic therapies like Diabetes, Heart, Neuro).
- Domestic Trade Generics: Apne brand name se generic medicines bechte hain jo distribution network ke through tier-2 aur tier-3 cities me supply hoti hain.
- Exports: International markets (Semi-regulated & Regulated) me medicines supply karte hain.
- Revenue Mix (Approx):
- CDMO (B2B): ~50-55%
- Domestic Trade Generics: ~35-40%
- Exports: ~10-15% (Fastest growing segment)
- Competitive Advantage: Ye India ki Top 5 CDMO companies me aate hain (Domestic Formulations). Inke paas Dehradun me 4 specialized manufacturing plants hain. “Asset Light” model par kaam karte hain kyunki R&D cost client bear karta hai.
2️⃣ Industry & Sector Analysis
- Sector Status: Indian CDMO sector ek Structural Bull Run me hai. Global pharma companies “China Plus One” strategy ke tehat India me manufacturing shift kar rahi hain.
- Growth Drivers:
- Chronic Disease Boom: India me lifestyle diseases (Sugar, BP) badh rahi hain, jiske liye lifelong medicines chahiye. Windlas ka portfolio isi par focused hai.
- Outsourcing Trend: Badi pharma companies manufacturing outsource kar rahi hain taaki wo marketing aur new drug discovery par focus kar sakein.
- Major Competitors: Akums Drugs (Market Leader), Synokem, Theon Pharma. (Listed peers: Innova Captab).
3️⃣ Latest Financial Performance (Consolidated)
Data Source: Screener.in / BSE Filings (Figures in ₹ Cr)
| Metric | FY 2023 | FY 2024 | FY 2025 | Q3 FY26 (Latest)* |
| Revenue | 513 | 631 | 760 | 233 |
| Op. Profit (EBITDA) | 60 | 78 | 94 | 24 |
| OPM % | 12% | 12% | 12% | ~10.5% |
| Net Profit (PAT) | 43 | 58 | 61 | 15 |
| EPS (₹) | 20.38 | 27.96 | 28.94 | 7.12 (Qtr) |
| ROE % | 10% | 13% | 12% | ~12% |
| Debt/Equity | 0.01 | 0.01 | 0.04 | 0.04 |
(Note: Q3 FY26 ended Dec 31, 2025. Comparison YoY: Revenue +20%, but Profit -3.2% due to margin pressure.)
- Analysis:
- Revenue Growth: Top-line growth shandaar hai (+20% in Q3). Ye dikhata hai ki demand strong hai aur market share badh raha hai.
- Margin Pressure: Latest quarter (Q3 FY26) me margins girkar ~10.5% ho gaye hain (vs 12-13% historical). Iska karan raw material cost aur ESOP expenses hain.
- Clean Balance Sheet: Company virtually Debt-Free hai (D/E 0.04). Cash rich status inhein high interest rates environment me protect karta hai.
- Cash Flow: Operating Cash Flow positive hai, lekin free cash flow capex ki wajah se fluctuate hota hai.
4️⃣ Management & Shareholding (Latest Pattern)
- Promoter Holding (~62%): Promoters (Windlass Family) ka stake stable hai. Koi major selling nahi hui hai. Pledging: NIL.
- Mutual Funds (~6.6%): ICICI Prudential Pharma Fund ne apna stake maintain kiya hai. Institutional interest small-cap category me decent hai.
- Public (Retail): ~25%.
- Governance: Management transparent hai. IPO ke baad se guidance meet ki hai. Capital allocation disciplined raha hai (Buyback bhi kiya tha past me).
5️⃣ Valuation (Latest Market Data)
- Current PE: ~27x
- Price to Book (PB): ~3.3x
- EV/EBITDA: ~14.6x
- Peer Comparison:
- Innova Captab: Trades at ~30-35x PE.
- Akums Drugs: (Newly Listed) Higher valuation.
- Windlas: Relative to growth (20% revenue growth), valuation Reasonable (Fair) hai. Bahut sasta nahi, par mehenga bhi nahi.
- Fair Value View: Agar company 12-13% margins wapas hasil kar leti hai, to EPS growth valuation ko justify kar degi. Current price future growth ko partially price-in kar chuka hai.
6️⃣ Future Growth Triggers (3–5 Years)
- Injectables Expansion: Company ab solid orals (tablets) se aage badhkar Injectables segment me enter kar rahi hai. Ye high-margin business hai.
- Export Market: US aur Europe me direct business badhane ki koshish. Agar export share 15% se 25% jata hai, to margins significantly expand honge.
- Capacity Addition: Dehradun plant me automation aur capacity badhane ka kaam chal raha hai taaki badhti demand puri ki ja sake.
7️⃣ Present Situation (Current Outlook)
- Stock Phase: Correction/Consolidation. Strong revenue growth ke bawajood, margins girne ki wajah se stock thoda pressure feel kar raha hai.
- Short-Term: Q3 ke mixed results (High Revenue, Low Profit) stock ko range-bound rakh sakte hain (₹800-₹900 zone).
- Long-Term: Growth story intact hai. Revenue consistently badh raha hai, profit catch-up karega jab cost pressures ease honge.
8️⃣ Risk & Red Flags
- Margin Volatility: Raw material (API) prices badhne par ye turant cost pass-on nahi kar paate (fixed contracts hote hain). Q3 FY26 me yahi hua.
- Regulatory Risk: Pharmaceutical company hone ke naate, kisi bhi plant par USFDA ya regulatory ban aana bada risk hota hai. (Currently status: Clear).
- Client Concentration: Top 5 clients se bada hissa revenue aata hai. Agar koi bada client chala gaya to impact hoga.
9️⃣ Final Verdict
- Summary: Windlas Biotech ek “Clean Small-Cap” hai—Debt free, growing revenue, aur stable promoters. Q3 me margin pressure ek temporary hiccup lag raha hai, structural issue nahi.
- For Conservative Investors: Hold. Small-cap volatility bardasht kar sakein tabhi enter karein. Balance sheet safe hai.
- For Aggressive Investors: Accumulate on Dips. Agar stock ₹800 ke aas-paas milta hai, to risk-reward ratio bohot attractive ho jayega.
- Target Expectation: Considering 15-18% EPS growth estimate, stock fair value ₹1,050 – ₹1,150 range me ho sakti hai agle 1.5 – 2 saal me.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.